Ovarian Cancer

Created:   4/18/2012
Contains:  13 items
Volume 55, Number 1, March 2012 John R. van Nagell, Jr., MD, Markey Cancer Center, Division of Gynecologic Oncology, University of Kentucky, Lexington, KentuckyLarry J. Copeland, MD, James Cancer Center, Division of Gynecologic Oncology, The Ohio State University, Columbus, OhioOvarian cancer is the leading cause of gynecologic cancer mortality in the United States. Many of the significant advances in the understanding of the pathophysiology and treatment of ovarian cancer are highlighted in this symposia, including data suggesting that regular screening may result in a decrease in ovarian cancer stage at detection; survival of patients with epithelial ovarian cancer is directly related to the volume of residual disease after surgical cytoreduction; the majority of patients with advanced-stage epithelial ovarian cancer will eventually develop recurrent disease and are candidates for treatment with other cytotoxic agents or targeted molecular genetic therapies. In addition, advances in symptoms management and palliative care that have improved the quality of life in patients in whom cure is not possible are presented.